摘要
目的:探讨立体定向放疗(stereotactic body radiotherapy,SBRT)对不可手术切除的肝转移癌患者的临床疗效。方法:回顾性分析2018年3月至2019年11月同济大学附属东方医院收治的28例肝转移癌患者的临床资料。予4D-CT或呼吸门控技术进行CT模拟定位,予肝转移病灶50Gy/10f的剂量分割模式。结果:所有患者均顺利完成全程放疗。半年和1年的总生存率(overall survival,OS)为95.0%和70.1%。1年的局部控制率(local control,LC)为92.2%。常见的不良反应为Ⅰ~Ⅱ级的恶心、纳差、腹痛等,无Ⅲ级以上的不良反应发生。结论:以50Gy/10f分割模式的立体定向放射治疗技术治疗肝转移癌安全有效。
Objective:To explore the clinical efficacy of stereotactic body radiotherapy(SBRT)for the treatment of patients with unresectable liver metastasis.Methods:Data of 28 patients with unresectable liver metastases were retrospectively analyzed.All patients were admitted to the Shanghai East Hospital from March 2018 to November 2019.Patients underwent 4D-CT or respiration gating for CT simulation.The prescription dose for the liver metastasis was 50 Gy in 10 fractions.Results:All patients successfully completed the SBRT treatment.The median overall survival was 7.4 months.The six months and one-year survival rates were 95.0%and 70.1%,respectively.The local control rate for one year was 92.2%.The most common toxicity was gradeⅠorⅡnausea,poor appetite,and abdominal pain.No gradeⅢor worse toxicity was found.Conclusions:SBRT with 50 Gy in 10 fractions is a safe and effective treatment for patients with unresectable liver metastasis.
作者
卢振国
孙君碟
向作林
卢欣
王爱华
袁骏
LU Zhen-guo;SUN Jun-die;XIANG Zuo-lin;LU Xin;WANG Ai-hua;YUAN Jun(Department of Radiation Oncology,Shanghai East Hospital,Tongji University School of Medicine,Shanghai 200120,China)
出处
《中国临床医学》
2020年第6期1007-1010,共4页
Chinese Journal of Clinical Medicine
基金
国家自然科学基金(81960525)
上海市科技创新项目(19DZ1930903)
上海自然科学基金(17zr1405300)
上海科技支撑项目(17411962600)
上海市浦东新区科技和经济委员会民生项目(PKJ2018-Y02)
江西省自然科学基金(20192BAB205071).
关键词
肝转移癌
立体定向放疗
结直肠癌
liver metastasis
stereotactic body radiotherapy(SBRT)
colorectal cancer
